EVRY, France--(BUSINESS WIRE)--Regulatory News : IntegraGen (FR0010908723 – ALINT – Eligible PEA SME), a company specializing in genomics of cancer and rare genetic diseases, which carries out genomic and data analyses, which can be interpreted for academic and private laboratories, gives an update on the hearing held today before the Commercial Court of Évry, in the context of the legal remedy procedure opened on 15 June 2026.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
EVRY, France--(BUSINESS WIRE)--Regulatory News : IntegraGen (FR0010908723 – ALINT – Eligible PEA SME), a company specializing in genomics of cancer and rare genetic diseases, which carries out genomic and data analyses, which can be interpreted for academic and private laboratories, gives an update on the hearing held today before the Commercial Court of Évry, in the context of the legal remedy procedure opened on 15 June 2026.